A Randomized, Double-Blind Phase II Trial of Surgery, Radiation Therapy plus Temozolomide and Pembrolizumab with and without HSPPC-96 in Newly diagnosed Glioblastoma (GBM) Save

Date Added
January 8th, 2019
PRO Number
Pro00083430
Researcher
David Cachia

List of Studies

Silhouette
Keywords
Glioblastoma
Summary

The purpose of this study is to find out if adding a chemotherapy drug called pembrolizumab and a vaccine to standard of care treatment (temodar and radiation therapy) for glioblastoma improves survival.

Institution
MUSC
Recruitment Contact
John Keller
843-792-2209
kellej@musc.edu

Change_preferences

-- OR --

Create_login